{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:50:08Z","timestamp":1791507008839,"version":"4.3.4"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"vor","delay-in-days":86,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-16514-0","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T08:44:23Z","timestamp":1784105063000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Adjuvant chemotherapy with or without EGFR-TKIs for resected EGFR-mutated non-small cell lung cancer: a pooled analysis of four randomized controlled trials"],"prefix":"10.1186","volume":"26","author":[{"given":"Sui","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feilong","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiafu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6450-8989","authenticated-orcid":false,"given":"Jiangbo","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"issue":"1","key":"16514_CR1","volume":"76","author":"RL Siegel","year":"2026","unstructured":"Siegel RL, Kratzer TB, Wagle NS, Sung H, Jemal A. Cancer statistics, 2026. CA Cancer J Clin. 2026;76(1):e70043.","journal-title":"CA Cancer J Clin"},{"key":"16514_CR2","doi-asserted-by":"crossref","unstructured":"NSCLC Meta-analyses Collaborative Group; Arriagada R, Auperin A, Burdett S, Higgins JP, Johnson DH, et al. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet. 2010;375(9722):1267\u201377.","DOI":"10.1016\/S0140-6736(10)60059-1"},{"issue":"5","key":"16514_CR3","first-page":"387","volume":"75","author":"M Borgeaud","year":"2025","unstructured":"Borgeaud M, Olivier T, Bar J, Saw SPL, Parikh K, Banna GL, et al. Personalized care for patients with EGFR-mutant nonsmall cell lung cancer: navigating early to advanced disease management. CA Cancer J Clin. 2025;75(5):387\u2013409.","journal-title":"CA Cancer J Clin"},{"issue":"7","key":"16514_CR4","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1200\/JCO.20.01820","volume":"39","author":"WZ Zhong","year":"2021","unstructured":"Zhong WZ, Wang Q, Mao WM, Xu ST, Wu L, Wei YC, et al. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC: final overall survival analysis of CTONG1104 phase III trial. J Clin Oncol. 2021;39(7):713\u201322.","journal-title":"J Clin Oncol"},{"issue":"11","key":"16514_CR5","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/S2213-2600(18)30277-7","volume":"6","author":"D Yue","year":"2018","unstructured":"Yue D, Xu S, Wang Q, Li X, Shen Y, Zhao H, et al. Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial. Lancet Respir Med. 2018;6(11):863\u201373.","journal-title":"Lancet Respir Med"},{"issue":"9","key":"16514_CR6","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/S2213-2600(21)00134-X","volume":"9","author":"J He","year":"2021","unstructured":"He J, Su C, Liang W, Xu S, Wu L, Fu X, et al. Icotinib versus chemotherapy as adjuvant treatment for stage II-IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial. Lancet Respir Med. 2021;9(9):1021\u20139.","journal-title":"Lancet Respir Med"},{"issue":"1","key":"16514_CR7","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/S1470-2045(17)30729-5","volume":"19","author":"WZ Zhong","year":"2018","unstructured":"Zhong WZ, Wang Q, Mao WM, Xu ST, Wu L, Shen Y, et al. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1\u2013N2) EGFR-mutant NSCLC (ADJUVANT\/CTONG1104): a randomised, open-label, phase 3 study. Lancet Oncol. 2018;19(1):139\u201348.","journal-title":"Lancet Oncol"},{"issue":"1","key":"16514_CR8","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1186\/s12885-022-09444-0","volume":"22","author":"P Zhao","year":"2022","unstructured":"Zhao P, Zhen H, Zhao H, Zhao L, Cao B. Efficacy and safety of adjuvant EGFR-TKIs for resected non-small cell lung cancer: a systematic review and meta-analysis based on randomized control trials. BMC Cancer. 2022;22(1):328.","journal-title":"BMC Cancer"},{"issue":"1","key":"16514_CR9","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1186\/s12885-023-11194-6","volume":"23","author":"SL Zhang","year":"2023","unstructured":"Zhang SL, Yi XF, Huang LT, Sun L, Ma JT, Han CB. Rational application of EGFR-TKI adjuvant therapy in patients with completely resected stage IB-IIIA EGFR-mutant NSCLC: a systematic review and meta-analysis of 11 randomized controlled trials. BMC Cancer. 2023;23(1):719.","journal-title":"BMC Cancer"},{"issue":"18","key":"16514_CR10","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1056\/NEJMoa2027071","volume":"383","author":"YL Wu","year":"2020","unstructured":"Wu YL, Tsuboi M, He J, John T, Grohe C, Majem M, et al. Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer. N Engl J Med. 2020;383(18):1711\u201323.","journal-title":"N Engl J Med"},{"key":"16514_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2026.103138","volume":"146","author":"S Zhao","year":"2026","unstructured":"Zhao S, Liu X, Wang J, Tang B, Long Q, Tang X, et al. Perioperative strategies for resectable EGFR-Mutant NSCLC: evidence hierarchy and clinical decision-making. Cancer Treat Rev. 2026;146:103138.","journal-title":"Cancer Treat Rev"},{"key":"16514_CR12","doi-asserted-by":"crossref","unstructured":"Delasos L, Hassan KA. Role of EGFR-TKIs in Nonmetastatic Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: A Comprehensive Review. JCO Oncol Pract. 2026:OP2501061.","DOI":"10.1200\/OP-25-01061"},{"key":"16514_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2023.104010","volume":"186","author":"X Cui","year":"2023","unstructured":"Cui X, Li X, Lv C, Yan S, Wang J, Wu N. Efficacy and safety of adjuvant EGFR TKI alone and in combination with chemotherapy for resected EGFR mutation-positive non-small cell lung cancer: A Bayesian network meta-analysis. Crit Rev Oncol Hematol. 2023;186:104010.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"5","key":"16514_CR14","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/ki.2008.217","volume":"74","author":"KJ Jager","year":"2008","unstructured":"Jager KJ, van Dijk PC, Zoccali C, Dekker FW. The analysis of survival data: the Kaplan-Meier method. Kidney Int. 2008;74(5):560\u20135.","journal-title":"Kidney Int"},{"issue":"1","key":"16514_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","volume":"17","author":"AR Jadad","year":"1996","unstructured":"Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1\u201312.","journal-title":"Control Clin Trials"},{"key":"16514_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PIC, J\u00fcni P, Moher D, Oxman AD, et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.","journal-title":"BMJ"},{"issue":"4","key":"16514_CR17","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.jclinepi.2010.09.011","volume":"64","author":"GH Guyatt","year":"2011","unstructured":"Guyatt GH, Oxman AD, Sch\u00fcnemann HJ, Tugwell P, Knottnerus A. GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. J Clin Epidemiol. 2011;64(4):380\u20132.","journal-title":"J Clin Epidemiol"},{"issue":"3","key":"16514_CR18","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1097\/EDE.0000000000001180","volume":"31","author":"MB Mathur","year":"2020","unstructured":"Mathur MB, VanderWeele TJ. Robust metrics and sensitivity analyses for meta-analyses of heterogeneous effects. Epidemiology. 2020;31(3):356\u20138.","journal-title":"Epidemiology"},{"issue":"2","key":"16514_CR19","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1056\/NEJMoa2304594","volume":"389","author":"M Tsuboi","year":"2023","unstructured":"Tsuboi M, Herbst RS, John T, Kato T, Majem M, Groh\u00e9 C, et al. Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC. N Engl J Med. 2023;389(2):137\u201347.","journal-title":"N Engl J Med"},{"issue":"9","key":"16514_CR20","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1016\/j.jtho.2023.05.015","volume":"18","author":"T John","year":"2023","unstructured":"John T, Groh\u00e9 C, Goldman JW, Shepherd FA, de Marinis F, Kato T, et al. Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC: Updated Analysis From the Phase 3 ADAURA Trial. J Thorac Oncol. 2023;18(9):1209\u201321.","journal-title":"J Thorac Oncol"},{"key":"16514_CR21","doi-asserted-by":"publisher","unstructured":"Herbst RS, Wu YL, John T, Grohe C, Majem M, Wang J, et al. Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial. J Clin Oncol. 2023;41(10):1830\u20131840. https:\/\/doi.org\/10.1200\/JCO.22.02186. Epub 2023 Jan 31. Erratum in: J Clin Oncol. 2023;41(22):3877.","DOI":"10.1200\/JCO.22.02186"},{"issue":"3","key":"16514_CR22","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.jtho.2021.10.014","volume":"17","author":"YL Wu","year":"2022","unstructured":"Wu YL, John T, Grohe C, Majem M, Goldman JW, Kim SW, et al. Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC. J Thorac Oncol. 2022;17(3):423\u201333.","journal-title":"J Thorac Oncol"},{"issue":"2","key":"16514_CR23","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/S1470-2045(25)00643-6","volume":"27","author":"L Zhang","year":"2026","unstructured":"Zhang L, Zhang X, Wu L, Xing W, Liu C, Zhang P, et al. Aumolertinib as adjuvant therapy in resected EGFR-mutated non-small-cell lung cancer (ARTS): a double-blind, multicentre, randomised, controlled, phase 3 trial. Lancet Oncol. 2026;27(2):159\u201368.","journal-title":"Lancet Oncol"},{"issue":"10","key":"16514_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0140794","volume":"10","author":"S Feng","year":"2015","unstructured":"Feng S, Wang Y, Cai K, Wu H, Xiong G, Wang H, et al. Randomized adjuvant chemotherapy of EGFR-mutated non-small cell lung cancer patients with or without icotinib consolidation therapy. PLoS ONE. 2015;10(10):e0140794.","journal-title":"PLoS ONE"},{"issue":"1","key":"16514_CR25","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/s41392-025-02358-w","volume":"10","author":"N Li","year":"2025","unstructured":"Li N, Ou W, Cheng C, You J, Yang L, Chen FX, et al. Adjuvant icotinib for resected EGFR-mutated stage II-IIIA non-small-cell lung cancer (ICTAN, GASTO1002): a randomized comparison study. Signal Transduct Target Ther. 2025;10(1):273.","journal-title":"Signal Transduct Target Ther"},{"issue":"6","key":"16514_CR26","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1245\/s10434-014-3586-9","volume":"21","author":"N Li","year":"2014","unstructured":"Li N, Ou W, Ye X, Sun HB, Zhang L, Fang Q, et al. Pemetrexed-carboplatin adjuvant chemotherapy with or without gefitinib in resected stage IIIA-N2 non-small cell lung cancer harbouring EGFR mutations: a randomized, phase II study. Ann Surg Oncol. 2014;21(6):2091\u20136.","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"16514_CR27","doi-asserted-by":"publisher","first-page":"385","DOI":"10.3816\/CLC.2006.n.021","volume":"7","author":"AM Davies","year":"2006","unstructured":"Davies AM, Ho C, Lara PN Jr, Mack P, Gumerlock PH, Gandara DR. Pharmacodynamic separation of epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy in non-small-cell lung cancer. Clin Lung Cancer. 2006;7(6):385\u20138.","journal-title":"Clin Lung Cancer"},{"issue":"1","key":"16514_CR28","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s12935-025-03734-w","volume":"25","author":"YC Fu","year":"2025","unstructured":"Fu YC, Liang SB, Luo M, Wang XP. Intratumoral heterogeneity and drug resistance in cancer. Cancer Cell Int. 2025;25(1):103.","journal-title":"Cancer Cell Int"},{"issue":"3","key":"16514_CR29","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.3390\/curroncol31030122","volume":"31","author":"DJ Stewart","year":"2024","unstructured":"Stewart DJ, Cole K, Bosse D, Brule S, Fergusson D, Ramsay T. Population survival kinetics derived from clinical trials of potentially curable lung cancers. Curr Oncol. 2024;31(3):1600\u201317.","journal-title":"Curr Oncol"},{"issue":"7","key":"16514_CR30","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1200\/JCO.20.03297","volume":"39","author":"SN Waqar","year":"2021","unstructured":"Waqar SN, Govindan R. Adjuvant therapy with EGFR tyrosine kinase inhibitors: tempering great expectations with realism. J Clin Oncol. 2021;39(7):697\u2013700.","journal-title":"J Clin Oncol"},{"issue":"5","key":"16514_CR31","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1002\/cncr.35112","volume":"130","author":"HJ West","year":"2024","unstructured":"West HJ, Pennell NA. Lessons from ADAURA: can we improve on a positive trial? Cancer. 2024;130(5):659\u201364.","journal-title":"Cancer"},{"key":"16514_CR32","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S587428","volume":"20","author":"L Xiong","year":"2026","unstructured":"Xiong L, Yang X, Yuan H, Qin L, Lin B, Chen F, et al. Perioperative EGFR-targeted therapy in resectable EGFR-mutated NSCLC: a narrative review from drug design to pain-informed MRD-guided care. Drug Des Devel Ther. 2026;20:587428.","journal-title":"Drug Des Devel Ther"},{"issue":"Suppl 4","key":"16514_CR33","doi-asserted-by":"publisher","first-page":"S387","DOI":"10.21037\/tlcr.2019.09.02","volume":"8","author":"J Jassem","year":"2019","unstructured":"Jassem J. Adjuvant EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: still an investigational approach. Transl Lung Cancer Res. 2019;8(Suppl 4):S387\u201390.","journal-title":"Transl Lung Cancer Res"},{"key":"16514_CR34","doi-asserted-by":"publisher","first-page":"1002714","DOI":"10.3389\/fonc.2022.1002714","volume":"12","author":"NT Bain","year":"2022","unstructured":"Bain NT, Wang Y, Arulananda S. Minimal residual disease in EGFR-mutant non-small-cell lung cancer. Front Oncol. 2022;12:1002714.","journal-title":"Front Oncol"},{"issue":"4","key":"16514_CR35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0231546","volume":"15","author":"DG Hyun","year":"2020","unstructured":"Hyun DG, Choi CM, Lee DH, Kim SW, Yoon S, Kim WS, et al. Outcomes according to initial and subsequent therapies following intracranial progression in patients with EGFR-mutant lung cancer and brain metastasis. PLoS ONE. 2020;15(4):e0231546.","journal-title":"PLoS ONE"},{"issue":"4","key":"16514_CR36","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s11523-024-01073-w","volume":"19","author":"S Zhou","year":"2024","unstructured":"Zhou S, Kishi N, Alerasool P, Rohs NC. Adverse Event Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-small Cell Lung Cancer: An Updated Meta-analysis. Target Oncol. 2024;19(4):547\u201364.","journal-title":"Target Oncol"},{"issue":"7","key":"16514_CR37","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1200\/JCO.23.02219","volume":"42","author":"PA J\u00e4nne","year":"2024","unstructured":"J\u00e4nne PA, Planchard D, Kobayashi K, Cheng Y, Lee CK, Valdiviezo N, et al. CNS Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth Factor Receptor-Mutated Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2024;42(7):808\u201320.","journal-title":"J Clin Oncol"},{"issue":"3","key":"16514_CR38","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/jjco\/hyae173","volume":"55","author":"N Awano","year":"2025","unstructured":"Awano N, Yoh K, Usui K, Hosomi Y, Kishi K, Naka G, et al. Outcome of osimertinib-treated patients with epidermal growth factor receptor mutation-positive nonsmall cell lung cancer requiring dose reduction: a secondary analysis of the Reiwa study. Jpn J Clin Oncol. 2025;55(3):261\u20138.","journal-title":"Jpn J Clin Oncol"},{"key":"16514_CR39","doi-asserted-by":"publisher","first-page":"379","DOI":"10.2147\/OTT.S494112","volume":"18","author":"H Iso","year":"2025","unstructured":"Iso H, Yomota M, Shirakura Y, Yoshinaga T, Kawai S, Narita K, et al. Clinical impact of osimertinib dose reduction in the first-line setting on EGFR mutation-positive non-small cell lung cancer: a retrospective monocentric study. Onco Targets Ther. 2025;18:379\u201387.","journal-title":"Onco Targets Ther"},{"key":"16514_CR40","doi-asserted-by":"crossref","unstructured":"Yu M, Undergraduate CC, Gong Y, Md TT, Li Y, Fan H, et al. Efficacy and Safety of Aumolertinib\/Icotinib Combination Therapy for Naive EGFR-Mutant NSCLC Patients with Brain Metastases: A Phase I\/II Study. Neuro Oncol. 2026;28(6):1491\u2013501.","DOI":"10.1093\/neuonc\/noag036"},{"issue":"2","key":"16514_CR41","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.jtho.2025.10.009","volume":"21","author":"X Le","year":"2026","unstructured":"Le X, Baik C, Cho BC, Riess JW, Piotrowska Z, Johannes de Langen A, et al. Osimertinib plus Savolitinib in patients with EGFR-mutated advanced NSCLC with MET alterations after first-line Osimertinib: clinical outcomes, safety, and biomarker analysis: a brief report. J Thorac Oncol. 2026;21(2):318\u201327.","journal-title":"J Thorac Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16514-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16514-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16514-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:12:45Z","timestamp":1791504765000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16514-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16514"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16514-0","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"assertion":[{"value":"30 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1211"}}